PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 00250.74943	SERIAL NUMBER 09/203,676
	APPLICANTS Michael R. ZALUTSKY, et al.	
	FILING DATE December 1, 1998	GROUP ART UNIT 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES/NO	
KMC	WO 99/11294	03/1999	WIPO				
KMC	WO 98/08548	03/1998	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KMC	S. V. GOVINDAN, et al., "Labeling of Monoclonal Antibodies with Diethylenetriaminepentaacetic Acid-Appended Radionated Peptides Containing D-Amino Acids", Bioconjugate Chemistry, 1999 Mar.-Apr. 10 (2) 231-240.
	M. R. ZALUTSKY, et al., "RadioiodinationVia D-Amino Acid Peptide Enhances Tumor Targeting of an Internalizing Anti-EGFRvIII Monoclonal Antibody", Proceedings of the American Association for Cancer Research Annual Meeting, March 2000, No. 41, pp. 706.
	Y. ARANO, et al., "Conventional and High Yield Synthesis of DTPA-Conjugated Peptides: Application of a Monoreactive DTPA to DTPA-D-Phe-Octreotide Synthesis", Bioconjugate Chemistry, Vol. 8, 1997, pp. 442-446.
	T. M. BEHR, et al., "Reduction of the Renal Uptake of Radiolabeled Monoclonal Antibody Fragments by Cationic Amino Acids and Their Derivatives", Cancer Research, US, American Association for Cancer Research, Baltimore, MD, Vol. 55, 1 September 1995, pp. 3825-3834.
	K. ZIMMERMANN, et al., "A Triglycine Linker Improves Tumor Uptake and Biodistributions of 67-Cu-Labeled Anti-Neuroblastoma MAb chCE7 F(ab')2 Fragments - Reactivity Studies of the Pendant Carboxylic Group in a Macrocyclic Cu2+ Complex Towards Amide Formation and its Use as a Protein Labeling Agent", Nuclear Medicine and Biology, US, Elsevier Science Publishers, New York, NY, Vol. 26, No. 8, November 1999, pp. 943-950
	C. F. Foulon, et al., "Radioiodination Via D-Amino Acid Peptide Enhances Cellular Retention and Tumor Xenograft Targeting of an Internalizing Anti-Epidermal Growth Factor Receptor Variant III Monoclonal Antibody", Cancer Research, Vol. 60, 15 August 2000, pp. 4453-4460.
	M. R. ZALUTSKY, et al., "Astatine-211-Labeled Radiotherapeutics: an Emerging Approach to Targeted Alpha Particle Radiotherapy", Current Pharmaceutical Design, Vol. 6 September 2000, pp. 1433-1455.
	C. J. Reist, et al., "In Vitro and In Vivo Behavior of Radiolabeled Chimeric Anti-EGFRvIII Monoclonal Antibody: Comparison with its Murine Parent", Nuclear Medicine and Biology, US, Elsevier Science Publishers, New York, NY, Vol. 24, No. 7, 1 October 1997, pp. 639-647.
	C. J. Reist, et al., "Astatine-211-Labeling of Internalizing Anti-EGFRvIII Monoclonal Antibody Using N-Succinimidyl 5-'At!astato-3-Pyridinecarboxylate - Preservation of Immunoreactivity and in Vivo Localizing Capacity", Nuclear Medicine and Biology, US, Elsevier Science Publishers, New York, NY, Vol. 26, No. 4, May 1999, pp. 405-411.
	J. SUNDIN, et al., "High Yield Direct Br-Bromination of Monoclonal Antibodies Using Chloramine-T - Detection of Colorectal Carcinoma with Positron-Emitting Copper-64-Labeled Monoclonal Antibody", Nuclear Medicine and Biology, US, Elsevier Science Publishers, New York, NY, Vol. 26, No. 8, November 1999, pp. 923-929.
	R. STEIN, et al., "Targeting Human Cancer Xenografts with Monoclonal Antibodies Labeled Using Radioiodinated Diethylenetriaminepentaacetic Acid-Appended Peptides", Clinical Cancer Research, Vol. 5, No. Suppl., October 1999, pp. 3079s-3087s.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.